美国BioVex 
BioVex是私营生物技术公司，主要开发癌症和慢性感染性疾病的治疗药物和预防药物。该公司拥有两项独特的专利产品平台（OncoVEX 和ImmunoVEX）和一个功能基因组平台（NeuroVEX），这些技术都是基于单纯疱疹病毒的操作。
公司的主要癌症治疗药物 OncoVEX GM-CSF已经在临床试验中取得了很好的研究数据，此次融得的资金将使我们顺利完成临床2期研究。同时资金还将用于抗感染在研药物——一种生殖器疱疹疫苗的2期临床研究。

BioVex is a biotechnology company focused on the development and commercialization of biological treatments for cancer and the prevention of infectious disease.

Our lead cancer program, OncoVEXGM-CSF, is a first in class oncolytic vaccine or cancer destroying virus technology that works by replicating and spreading within solid tumors, causing the death of cancer cells while leaving surrounding healthy cells unharmed. The attenuated virus has also been constructed to induce a powerful systemic anti tumor immune response. OncoVEXGM-CSF has now been tested in >110 patients in a broad range of solid tumors including melanoma, head & neck cancer, breast cancer and pancreatic cancer. Both the direct cell killing and systemic immune mediated mechanisms of action of OncoVEX have been clearly validated in the clinic; OncoVEX routinely destroys tumors it is directly injected into and has led to overall disease responses in multiple patients in Phase II testing. Tumors resolved through OncoVEX treatment have not been known to recur.

In April 2008 the Company announced it had reached agreement on a pivotal study design in metastatic melanoma under the SPA process with the FDA. The Company plans to submit a second pivotal study SPA in Head and Neck cancer in mid 2009.

BioVex is a biotechnology company focused on the development and commercialization of biological treatments for cancer and the prevention of infectious disease

The Company is based in Woburn, Massachusetts, with an R&D facility in Oxford, UK